{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:13:00Z","timestamp":1792120380798,"version":"4.4.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>In recent years, replication-deficient viral vector vaccines have attracted much attention in the field of vaccine research and development due to their high safety and immunogenicity. These vaccines use genetic modifications to engineer viral vectors that make them unable to replicate but effective in expressing recombinant proteins and induce immune responses. Currently, replication-deficient adenovirus vectors and poxvirus vectors are widely used in vaccine R&amp;amp;D for a variety of infectious diseases in humans and animals, including AIDS, hepatitis B, pseudorabies, avian influenza, infectious bronchitis in poultry, and foot-and-mouth disease. Replication-deficient viral vaccines have been shown to effectively induce neutralizing antibodies and cellular immune responses, thereby providing effective immune protection. Future development of genetic engineering technology and continuous in-depth research on viral vectors should lead to replication-deficient viral vector platforms that have an essential role in preventing and controlling existing and emerging infectious diseases.<\/jats:p>","DOI":"10.3389\/fvets.2025.1535328","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:05:04Z","timestamp":1740985504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Research advances in replication-deficient viral vector vaccines"],"prefix":"10.3389","volume":"12","author":[{"given":"Junna","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.coviro.2011.07.009","article-title":"Viruses \u2013 from pathogens to vaccine carriers","volume":"1","author":"Small","year":"2011","journal-title":"Curr Opin Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored COVID-19 vaccine confers protection from SARS-CoV-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat Commun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia virus Ankara","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41541-018-0056-6","article-title":"Gallid herpesvirus 3 SB-1 strain as a recombinant viral vector for poultry vaccination","volume":"3","author":"Sadigh","year":"2018","journal-title":"NPJ Vaccines."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.vaccine.2021.01.018","article-title":"A broad spectrum HVT-H5 avian influenza vector vaccine which induces a rapid onset of immunity","volume":"39","author":"Reemers","year":"2021","journal-title":"Vaccine."},{"key":"B6","doi-asserted-by":"publisher","first-page":"583077","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging concepts and technologies in vaccine development","volume":"11","author":"Brisse","year":"2020","journal-title":"Front Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"122331","DOI":"10.1016\/j.lfs.2023.122331","article-title":"Vaccine development: current trends and technologies","volume":"336","author":"Poria","year":"2024","journal-title":"Life Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat Rev Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.virol.2005.09.020","article-title":"Replication-defective viruses as vaccines and vaccine vectors","volume":"344","author":"Dudek","year":"2006","journal-title":"Virology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.virusres.2015.07.013","article-title":"Development and applications of single-cycle infectious Influenza A Virus (sciIAV)","volume":"216","author":"Nogales","year":"2016","journal-title":"Virus Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jgm.2687","article-title":"Development of an AdEasy-based system to produce first- and second-generation adenoviral vectors with tropism for CAR- or CD46-positive cells","volume":"15","author":"Janssen","year":"2013","journal-title":"J Gene Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1089\/hum.1998.9.11-1587","article-title":"Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing \u03b11-antitrypsin after systemic delivery","volume":"9","author":"O'Neal","year":"1998","journal-title":"Hum Gene Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1128\/JVI.73.7.6048-6055.1999","article-title":"Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3","volume":"73","author":"Gorziglia","year":"1999","journal-title":"J Virol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.3390\/v15122378","article-title":"Evolving horizons: adenovirus vectors' timeless influence on cancer, gene therapy and vaccines","volume":"15","author":"Trivedi","year":"2023","journal-title":"Viruses."},{"key":"B18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.biotechadv.2008.10.003","article-title":"From the first to the third generation adenoviral vector: what parameters are governing the production yield?","volume":"27","author":"Dormond","year":"2009","journal-title":"Biotechnol Adv."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1004594","DOI":"10.1371\/journal.ppat.1004594","article-title":"A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy","volume":"11","author":"Pereira","year":"2015","journal-title":"PLoS Pathog."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/j.vaccine.2011.01.083","article-title":"Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine","volume":"29","author":"Miyata","year":"2011","journal-title":"Vaccine."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1046\/j.1365-2249.2001.01540.x","article-title":"Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols","volume":"124","author":"Yoshida","year":"2001","journal-title":"Clin Exp Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","article-title":"A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.3390\/ijms21144821","article-title":"Non-human primate-derived adenoviruses for future use as oncolytic agents?","volume":"21","author":"Bots","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.virol.2013.05.041","article-title":"Adenoviruses isolated from wild gorillas are closely related to human species C viruses","volume":"444","author":"Duncan","year":"2013","journal-title":"Virology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"579872","DOI":"10.3389\/fimmu.2020.579872","article-title":"Innate immune responses to chimpanzee adenovirus vector 155 vaccination in mice and monkeys","volume":"11","author":"Collignon","year":"2020","journal-title":"Front Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1038\/s41467-022-33649-3","article-title":"ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves","volume":"13","author":"de Jong","year":"2022","journal-title":"Nat Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e00265","DOI":"10.1128\/JVI.00265-20","article-title":"A new gorilla adenoviral vector with natural lung tropism avoids liver toxicity and is amenable to capsid engineering and vector retargeting","volume":"94","author":"Lu","year":"2020","journal-title":"J Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12936-017-1911-z","article-title":"New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model","volume":"16","author":"Limbach","year":"2017","journal-title":"Malar J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS ONE."},{"key":"B32","doi-asserted-by":"publisher","first-page":"eabj1996","DOI":"10.1126\/scitranslmed.abj1996","article-title":"GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults","volume":"14","author":"Lanini","year":"2022","journal-title":"Sci Transl Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0008459","DOI":"10.1371\/journal.pntd.0008459","article-title":"A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C","volume":"14","author":"Napolitano","year":"2020","journal-title":"PLoS Negl Trop Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2079323","DOI":"10.1080\/21645515.2022.2079323","article-title":"Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses","volume":"18","author":"Shoushtari","year":"2022","journal-title":"Hum Vaccin Immunother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1038\/s41598-020-60238-5","article-title":"Characterization of a species E adenovirus vector as a Zika virus vaccine","volume":"10","author":"Bullard","year":"2020","journal-title":"Sci Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"887729","DOI":"10.3389\/fcimb.2022.887729","article-title":"Mucosal vaccination: a promising alternative against flaviviruses","volume":"12","author":"Luria-P\u00e9rez","year":"2022","journal-title":"Front Cell Infect Microbiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1128\/jvi.66.4.2086-2095.1992","article-title":"High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model","volume":"66","author":"Jacobs","year":"1992","journal-title":"J Virol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0202820","DOI":"10.1371\/journal.pone.0202820","article-title":"Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge","volume":"13","author":"Cox","year":"2018","journal-title":"PLoS ONE."},{"key":"B39","doi-asserted-by":"publisher","first-page":"12907","DOI":"10.1128\/JVI.77.23.12907-12913.2003","article-title":"Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2","volume":"77","author":"Jaiswal","year":"2003","journal-title":"J Virol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.micinf.2005.05.023","article-title":"Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis","volume":"8","author":"Appaiahgari","year":"2006","journal-title":"Microbes Infect."},{"key":"B41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0928-0197(98)00038-5","article-title":"Defective adenoviruses as novel vaccines for the Flaviviridae","volume":"10","author":"Stephenson","year":"1998","journal-title":"Clin Diagn Virol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.vaccine.2005.08.091","article-title":"Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge","volume":"24","author":"Breathnach","year":"2006","journal-title":"Vaccine."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.vaccine.2008.01.016","article-title":"Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions","volume":"26","author":"Veits","year":"2008","journal-title":"Vaccine."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/vaccines10091516","article-title":"Development of modified vaccinia virus ankara-based vaccines: advantages and applications","volume":"10","author":"Orlova","year":"2022","journal-title":"Vaccines."},{"key":"B46","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus\u2013 and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci Transl Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1743-422X-8-49","article-title":"Avipoxviruses: infection biology and their use as vaccine vectors","volume":"8","author":"Weli","year":"2011","journal-title":"Virol J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1128\/jvi.66.8.4992-5001.1992","article-title":"High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells","volume":"66","author":"Wang","year":"1992","journal-title":"J Virol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"001644","DOI":"10.1099\/jgv.0.001644","article-title":"Alphaviruses: host pathogenesis, immune response, and vaccine & treatment updates","volume":"102","author":"Guerrero-Arguero","year":"2021","journal-title":"J Gen Virol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.3390\/v7052321","article-title":"Alphaviruses in gene therapy","volume":"7","author":"Lundstrom","year":"2015","journal-title":"Viruses."},{"key":"B52","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1128\/CVI.00037-07","article-title":"Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins","volume":"14","author":"Reap","year":"2007","journal-title":"Clin Vaccine Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.1016\/j.vaccine.2007.08.016","article-title":"Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus","volume":"25","author":"Reap","year":"2007","journal-title":"Vaccine."},{"key":"B54","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/sj.gt.3302618","article-title":"Use of adenoviral vectors as veterinary vaccines","volume":"12","author":"Ferreira","year":"2005","journal-title":"Gene Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.virol.2023.05.001","article-title":"Recombinant human adenovirus type 5 based vaccine candidates against GIIa- and GIIb-genotype porcine epidemic diarrhea virus induce robust humoral and cellular response in mice","volume":"584","author":"Miao","year":"2023","journal-title":"Virology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"8530273","DOI":"10.1155\/2019\/8530273","article-title":"Evaluation of the efficacy of a recombinant adenovirus expressing the spike protein of porcine epidemic diarrhea virus in pigs","volume":"2019","author":"Liu","year":"2019","journal-title":"Biomed Res Int."},{"key":"B57","doi-asserted-by":"publisher","first-page":"729879","DOI":"10.3389\/fvets.2021.729879","article-title":"A new look at vaccine strategies against PPRV focused on adenoviral candidates","volume":"8","author":"Rojas","year":"2021","journal-title":"Front Vet Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"105825","DOI":"10.1016\/j.antiviral.2024.105825","article-title":"An adenovirus-vectored vaccine based on the N protein of feline coronavirus elicit robust protective immune responses","volume":"223","author":"Wang","year":"2024","journal-title":"Antiviral Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e62496","DOI":"10.1371\/journal.pone.0062496","article-title":"Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness","volume":"8","author":"Vemula","year":"2013","journal-title":"PLoS ONE."},{"key":"B60","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jviromet.2010.02.019","article-title":"Immunogenicity and protective efficacy of a replication-defective infectious bronchitis virus vaccine using an adenovirus vector and administered in ovo","volume":"166","author":"Zeshan","year":"2010","journal-title":"J Virol Methods."},{"key":"B61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.vetimm.2011.05.007","article-title":"Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration","volume":"142","author":"Fern\u00e1ndez","year":"2011","journal-title":"Vet. Immunol. Immunopathol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1195314","DOI":"10.3389\/fcimb.2023.1195314","article-title":"Comparative evaluation of protective immunity against Francisella tularensis induced by subunit or adenovirus-vectored vaccines","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Cell Infect Microbiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0264-410X(01)00458-3","article-title":"Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD","volume":"20","author":"Gogev","year":"2002","journal-title":"Vaccine."},{"key":"B64","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0165-2427(00)00217-8","article-title":"The immunogenicity and efficacy of replication-defective and replication-competent bovine adenovirus-3 expressing bovine herpesvirus-1 glycoprotein gD in cattle","volume":"76","author":"Reddy","year":"2000","journal-title":"Vet Immunol Immunopathol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"108457","DOI":"10.1016\/j.fsi.2022.108457","article-title":"Development of a recombinant adenovirus-vectored vaccine against both infectious hematopoietic necrosis virus and infectious pancreatic necrosis virus in rainbow trout (Oncorhynchus mykiss)","volume":"132","author":"Li","year":"2023","journal-title":"Fish Shellfish Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12038-014-9495-z","article-title":"Co-expression of the C-terminal domain of Yersinia enterocolitica invasin enhances the efficacy of classical swine-fever-vectored vaccine based on human adenovirus","volume":"40","author":"Li","year":"2015","journal-title":"J Biosci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1128\/CVI.00426-15","article-title":"Evaluation of a fiber-modified adenovirus vector vaccine against foot-and-mouth disease in cattle","volume":"23","author":"Medina","year":"2016","journal-title":"Clin Vaccine Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.virol.2014.08.012","article-title":"Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine","volume":"70","author":"Diaz-San Segundo","year":"2014","journal-title":"Virology."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/S0264-410X(99)00545-9","article-title":"Single inoculation of replication-defective adenovirus-vectored vaccines at birth in piglets with maternal antibodies induces high level of antibodies and protection against pseudorabies","volume":"18","author":"Monteil","year":"2000","journal-title":"Vaccine."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.1128\/CMR.00105-19","article-title":"Immunomodulatory strategies in herpes simplex virus encephalitis","volume":"33","author":"Piret","year":"2020","journal-title":"Clin Microbiol Rev."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1134\/S0006297914130124","article-title":"Human herpes simplex virus: life cycle and development of inhibitors","volume":"79","author":"Kukhanova","year":"2014","journal-title":"Biochemistry."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e179483","DOI":"10.1172\/JCI179483","article-title":"Therapeutic vaccines for herpesviruses","volume":"134","author":"Cohen","year":"2024","journal-title":"J Clin Invest."},{"key":"B73","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1006\/viro.2001.1094","article-title":"Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection","volume":"288","author":"Da Costa","year":"2001","journal-title":"Virology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e46714","DOI":"10.1371\/journal.pone.0046714","article-title":"Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model","volume":"7","author":"Delagrave","year":"2012","journal-title":"PLoS ONE."},{"key":"B75","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jat.4404","article-title":"Nonclinical safety evaluation of two vaccine candidates for herpes simplex virus type 2 to support combined administration in humans","volume":"43","author":"Piras","year":"2023","journal-title":"J Appl Toxicol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/viro.1996.0328","article-title":"Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1","volume":"220","author":"Morrison","year":"1996","journal-title":"Virology."},{"key":"B77","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1016\/j.vaccine.2015.04.102","article-title":"Inactivated and subunit vaccines against porcine reproductive and respiratory syndrome: current status and future direction","volume":"33","author":"Renukaradhya","year":"2015","journal-title":"Vaccine."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1016\/j.vaccine.2016.09.048","article-title":"Commercial vaccines provide limited protection to NADC30-like PRRSV infection","volume":"34","author":"Bai","year":"2016","journal-title":"Vaccine."},{"key":"B79","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.vetimm.2004.09.022","article-title":"Construction and evaluation of genetically engineered replication-defective porcine reproductive and respiratory syndrome virus vaccine candidates","volume":"102","author":"Welch","year":"2004","journal-title":"Vet Immunol Immunopathol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1080\/22221751.2022.2108342","article-title":"African swine fever control and prevention: an update on vaccine development","volume":"11","author":"Urbano","year":"2022","journal-title":"Emerg Microbes Infect."},{"key":"B81","first-page":"107","article-title":"Establishment of a reverse genetics system for feline calicivirus and construction of an attenuated strain","volume":"56","author":"Yu","year":"2024","journal-title":"Anim Husband Vet Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"108383","DOI":"10.1016\/j.intimp.2021.108383","article-title":"Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV","volume":"102","author":"Lv","year":"2022","journal-title":"Int Immunopharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3390\/v14061317","article-title":"Prevention and control of porcine epidemic diarrhea: the development of recombination-resistant live attenuated vaccines","volume":"14","author":"Niu","year":"2022","journal-title":"Viruses."},{"key":"B85","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1186\/s12864-021-08061-8","article-title":"Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen","volume":"22","author":"Sheerin","year":"2021","journal-title":"BMC Genomics."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/infdis\/jiy411","article-title":"A Replicating single-cycle adenovirus vaccine against Ebola virus","volume":"218","author":"Anguiano-Zarate","year":"2018","journal-title":"J Infect Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.virol.2015.02.012","article-title":"PRRSV structure, replication and recombination: origin of phenotype and genotype diversity","volume":"479","author":"Kappes","year":"2015","journal-title":"Virology."},{"key":"B88","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fvets.2019.00038","article-title":"Key gaps in the knowledge of the porcine respiratory reproductive syndrome virus (PRRSV)","volume":"6","author":"Montaner-Tarbes","year":"2019","journal-title":"Front Vet Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/vaccines9040362","article-title":"Porcine reproductive and respiratory syndrome modified live virus vaccine: a \u201cleaky\u201d vaccine with debatable efficacy and safety","volume":"9","author":"Zhou","year":"2021","journal-title":"Vaccines."},{"key":"B90","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.vetimm.2006.05.001","article-title":"Recombinant adenovirus expressing GP5 and M fusion proteins of porcine reproductive and respiratory syndrome virus induce both humoral and cell-mediated immune responses in mice","volume":"113","author":"Jiang","year":"2006","journal-title":"Vet Immunol Immunopathol."}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2025.1535328\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:05:08Z","timestamp":1740985508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2025.1535328\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":90,"alternative-id":["10.3389\/fvets.2025.1535328"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2025.1535328","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"article-number":"1535328"}}